<?xml version="1.0" encoding="UTF-8"?>
<p>JAK-STAT inhibitors, like baricitinib, fedratinib, and ruxolitinib are potent anti-inflammatory drugs that are approved for rheumatoid arthritis and myelofibrosis. Patients infected with SARS-CoV-2 often present increased levels of pro-inflammatory cytokines and may benefit from the use of these drugs. A case series reported clinical improvement in COVID-19 patients treated with baricitinib (
 <xref rid="B103" ref-type="bibr">103</xref>). These drugs are currently being tested in multiple randomized controlled trials.
</p>
